Table 2.

Oral mucositis assessment in clinical trials.

	Clinical trial
	Standard chemotherapy	Head and neck (chemo)radiotherapy	HSCT	Targeted agents	Immunotherapy
Recommended tool for clinician assessment	WHO	WHO accepted as standard by regulatory bodies. Another option is CTCAE	WHO	No consensus	No consensus
Frequency of assessment	Weekly and every time the symptoms manifest. Televisit/telehealth may complement this assessment	No consensus	Daily (if inpatient) Weekly (if feasible in outpatient setting)	At each cycle or clinic visit/telehealth appointment	At each cycle or clinic visit/telehealth appointment
Recommended PROM	OMWQ or OMDQ if a more frequent follow up schedule is needed OR PRO-CTCAE questions related to mucositis	OMWQ and OMDQ or PRO-CTCAE questions related to mucositis	OMWQ or OMDQ or PRO-CTCAE questions related to mucositis	No consensus	No consensus
Frequency of assessment	Weekly or more frequently in case of treatment at higher risk of mucositis	Weekly or more frequently in case of treatment at higher risk of mucositis	Daily if inpatient and using OMDQ. Weekly if feasible in outpatient setting	At each cycle or clinic visit/telehealth appointment	At each cycle or clinic visit/telehealth appointment
Biomarkers to consider	No biomarkers recommended	No biomarkers recommended	No biomarkers recommended	No biomarkers recommended	No biomarkers recommended